Best of JACC: Heart Failure 2020 Christopher M. O’Connor, MD, MACCPresident and Executive DirectorInovaHeart and Vascular InstituteEditor-in-Chief, JACC: Heart FailurePast President, Heart Failure Society of America]

Best of JACC: Heart Failure 2020 Christopher M. O’Connor, MD, MACCPresident and Executive DirectorInovaHeart and Vascular InstituteEditor-in-Chief, JACC: Heart FailurePast President, Heart Failure Society of America] Top Content Topic Areas for JACC-HF•Pharmacology•Right Heart Failure and Pulmonary Hypertension•Comorbidities•Basic Science/Translational Research/Pathophysiology•Clinical Trial Methodology and Predictive Models•Heart Failure with Preserved Ejection Fraction (HFpEF)•Biomarkers•Advanced Heart Failure/Mechanical Support•Heart Failure -Imaging•Heart Failure -Electrophysiology•Non-Pharmacologic Therapies•Special Populations and Global Health•Acute Heart Failure•Outcomes and Quality Innovative Initiatives •Dead Letter Office•Patient Perspectives•50thAnniversary of Cardiac Transplantation: Dedicated Issue•HF in Women-Special Issue•Editor’s Blog•International Advisory Board•Simultaneous pubs ACC20/HRS19/HFSA19•JACC-HF Position Papers•Cardiogenic Shock Issue 7/20 2020 Hot Topics•COVID-19 Rapid Reports •Clinical Trials•Biomarkers•Device Therapy•Inflammation and HF Recommendations1. Study sponsors and sites should exercise the option of following patients usingtelephone follow-up procedures, until the COVID-19 pandemic abates.2. Diagnostic procedures, such as echocardiography, andsome study interventions such as the implantation of an investigational study deviceshould be delayed until the COVID-19 pandemic abates,due to the absence of safety concerns or overwhelming evidence benefit.3. Trials under development or with central IRB capability areencouraged to consider central IRB use.4. Statistical consideration should account for asymmetricenrollment by geography, and analysis of results before and after a pre-specified date on whichCOVID-19 had a significant influence on trial conduct.5. Specific issues regarding adjudication definitions in light of COVID-19 infection should be adjusted in the clinical events committee manuals of operation.6. Encourage maintenance of the patient screening architecture for HF clinical trials so that screening may be quickly escalated again once the pandemic subsides, in as much as this can be accomplished safely and remotely.7. Consider geographically targeting sites for initiation that are less likelyto be influenced by the pandemic. Fiuzat et al. J Am CollCardiolHF. 2020 JACC: HF Expert Consensus Position Paper Cunningham J.W. et al. J Am CollCardiol. HF. 2020 LBCT / ACC 2020 Zeitler, E.P. et al. J Am CardiolHF. 2020; 8 (4): 251-64. Orban,M. et al. J Am CollCardiolHF, 2020; 8(4):265-76. Kelly, J.P. et al. J Am CollCardiolHF. 2020;8(4):280-8. JACC-HF ConclusionsGoals•Recruit the best authors•Recruit the best papers•Affiliate with societies and organizations•Affiliate with meetingsFeatures•Meeting Summaries•Special Focus Issues•Consensus Statements / Expert Forum Papers•Fast Track Review for Society Papers